STATE OF THE ART PAPER
Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009–2014
 
More details
Hide details
Submission date: 2015-12-29
Final revision date: 2016-02-04
Acceptance date: 2016-02-11
Online publication date: 2016-03-31
Publication date: 2018-04-13
 
Arch Med Sci 2018;14(3):569–571
 
KEYWORDS
TOPICS
ABSTRACT
Approximately 1% of the population suffers from rheumatoid arthritis (RA) worldwide (0.45% in Poland). The therapy consists of the use of disease-modifying antirheumatic drugs (DMARDs). Biologics are used in the form of the drug programme. Analysis of the NHF database demonstrated the sequence of conversion between drugs and time spent in a single treatment. In 2009, the patients would start the following treatments: adalimumab 5.8%; etanercept 14.4%; infliximab 23.1%; leflunomide 53.6%; rituximab 3%. After the first year 16% of patients changed therapy or abstained, and in the second year this situation affected 65% of patients. The following percentages maintained the same treatment in the last 6 years: infliximab 4%; adalimumab 15%; etanercept 21%; leflunomide on prescription was continued by 70%. Patients remain too long on the same therapy when it is inefficient. Achieving remission or low disease activity (DAS28 < 2.6) should take place within 6 months of starting therapy.
eISSN:1896-9151
ISSN:1734-1922